Peer-influenced content. Sources you trust. No registration required. This is HCN.
Dana-Farber Cancer Institute
The results of the trial, known as the RELATIVITY-047 study, were presented at the virtual ASCO Annual Meeting that took place June 4-8, 2021. The Dana-Farber Cancer Institute Investigators who co-led the study were thrilled to present that, despite PD-1 blocker nivolumab revolutionizing the treatment of patients with advanced melanoma, this fixed-dose combination of nivolumab and LAG-3 target relatlimab holds the cancer in check significantly longer than nivolumab alone.
Dermatology June 9th 2021
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH